Лечение солидных опухолей ингибиторами контрольных точек на фоне сопутствующей ВИЧ-инфекции: стоит ли рисковать?

Цель исследования ‒ представить имеющиеся данные о переносимости ингибиторов контрольных точек (ИКТ) у онкологических пациентов, отягощенных ВИЧ-инфекцией.

Материал и методы. Проведен поиск литературных источников, опубликованных в базах данных PubMed, Cochrane Library и UpToDate по февраль 2022 г.

Результаты. В статье изложены предпосылки и опыт применения ИКТ для лечения злокачественных опухолей у больных с сопутствующей ВИЧ-инфекцией.

Заключение. До недавнего времени наличие вирусных заболеваний, в т.ч. ВИЧ-инфекции, являлось одним из ключевых противопоказаний для назначения иммунотерапии. Однако последние научные публикации демонстрируют эффективность и хорошую переносимость ИКТ у онкологических пациентов, отягощенных ВИЧ-инфекцией. Дальнейшие проспективные исследования позволят определить потенциал иммунотерапии в клинической практике у данной категории больных.

1. Puronen C.E., Ford E.S., Uldrick T.S. Immunotherapy in People With HIV and Cancer. Front Immunol. 2019; 10: 2060. doi: 10.3389/fimmu.2019.02060.

2. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Gross- man Z., Dybul M., Oxenius A., Price D.A., Connors M., Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417(6884): 95–8. doi: 10.1038/417095a.

3. Fenwick C., Joo V., Jacquier P., Noto A., Banga R., Perreau M., Pantaleo G. T-cell exhaustion in HIV infection. Immunol Rev. 2019; 292(1): 149–63. doi: 10.1111/imr.12823.

4. Jubel J.M., Barbati Z.R., Burger C., Wirtz D.C., Schildberg F.A. The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020; 11: 487. doi: 10.3389/fimmu.2020.00487.

5. Cockerham L.R., Jain V., Sinclair E., Glidden D.V., Hartogenesis W., Hatano H., Hunt P.W., Martin J.N., Pilcher C.D., Sekaly R., McCune J.M., Hecht F.M., Deeks S.G. Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease. AIDS. 2014; 28(12): 1749–58. doi: 10.1097/QAD.0000000000000314.

6. Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8): 486–99. doi: 10.1038/nri3862.

7. van der Sluis R.M., Kumar N.A., Pascoe R.D., Zerbato J.M., Evans V.A., Dantanarayana A.I., Anderson J.L., Sékaly R.P., Fromentin R., Chomont N., Cameron P.U., Lewin S.R. Combination Immune Checkpoint Blockade to Reverse HIV Latency. J Immunol. 2020; 204(5): 1242–54. doi: 10.4049/jimmunol.1901191.

8. Chen H., Moussa M., Catalfamo M. The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure? Front Immunol. 2020; 11: 1223.

9. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., Ahmed R., Amara R.R. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009; 458(7235): 206–10. doi: 10.1038/nature07662.

10. Mylvaganam G.H., Chea L.S., Tharp G.K., Hicks S., Velu V., Iyer S.S., Deleage C., Estes J.D., Bosinger S.E., Freeman G.J., Ahmed R., Amara R.R. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight. 2018; 3(18). doi: 10.1172/jci.insight.122940.

11. Heppt M.V., Schlaak M., Eigentler T.K., Kähler K.C., Kiecker F., Loquai C., Meier F., Tomsitz D., Brenner N., Niesert A.C., Thonke R., Hauschild A., Berking C. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann Oncol. 2017; 28(12): 3104–6. doi: 10.1093/annonc/mdx538.

12. Chang E., Sabichi A.L., Kramer J.R., Hartman C., Royse K.E., White D.L., Patel N.R., Richardson P., Yellapragada S.V., Garcia J.M., Chiao E.Y. Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother. 2018; 41(8): 379–83. doi: 10.1097/CJI.0000000000000240.

13. Galanina N., Goodman A.M., Cohen P.R., Frampton G.M., Kurzrock R. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018; 6(10): 1129–35. doi: 10.1158/2326-6066.CIR-18-0121.

14. Ostios-Garcia L., Faig J., Leonardi G.C., Adeni A.E., Subegdjo S.J., Lydon C.A., Rangachari D., Huberman M.S., Sehgal K., Shea M., VanderLaan P.A., Cheng M.P., Marty F.M., Hammond S.P., Costa D.B., Awad M.M. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(7): 1037–42. doi: 10.1016/j.jtho.2018.03.031.

15. Cook M.R., Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019; 5(7): 1049–54. doi: 10.1001/jamaoncol.2018.6737.

16. Spano J.P., Veyri M., Gobert A., Guihot A., Perré P., Kerjouan M., Brosseau S., Cloarec N., Montaudié H., Helissey C., Flament T., Gounant V., Lavolé A., Poizot-Martin I., Katlama C. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. AIDS. 2019; 33(11): 13–9. doi: 10.1097/QAD.0000000000002298.

17. Uldrick T.S., Gonçalves P.H., Abdul-Hay M., Claeys A.J., Emu B., Ernstoff M.S., Fling S.P., Fong L., Kaiser J.C., Lacroix A.M., Lee S.Y., Lundgren L.M., Lurain K., Parsons C.H., Peeramsetti S., Ramaswami R., Sharon E., Sznol M., Wang C.J., Yarchoan R., Cheever M.A.; Cancer Immunotherapy Trials Network (CITN)-12 Study Team. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. JAMA Oncol. 2019; 5(9): 1332–9. doi: 10.1001/jamaoncol.2019.2244.

18. Gonzalez-Cao M., Morán T., Dalmau J., Garcia-Corbacho J., Bracht J.W.P., Bernabe R., Juan O., de Castro J., Blanco R., Drozdowskyj A., Argilaguet J., Meyerhans A., Blanco J., Prado J.G., Carrillo J., Clotet B., Massuti B., Provencio M., Molina-Vila M.A., Mayo de Las Casa C., Garzon M., Cao P., Huang C.Y., Martinez-Picado J., Rosell R. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. JAMA Oncol. 2020; 6(7): 1063–7. doi: 10.1001/jamaoncol.2020.0465.

19. Lavole A., Mazieres J., Schneider S., Brosseau S., Kiakouama L., Greillier L., Guihot A., Abbar B., Baron M., Makinson A., Langlais A., Morin F., Spano J.P., Cadranel J.; On behalf the French Cooperative Thoracic Intergroup (IFCT). Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer. 2021; 158: 146–50. doi: 10.1016/j.lungcan.2021.05.031.

20. Uldrick T.S., Adams S.V., Fromentin R., Roche M., Fling S.P., Gonçalves P.H., Lurain K., Ramaswami R., Wang C.J., Gorelick R.J., Welker J.L., O'Donoghue L., Choudhary H., Lifson J.D., Rasmussen T.A., Rhodes A., Tumpach C., Yarchoan R., Maldarelli F., Cheever M.A., Sékaly R., Chomont N., Deeks S.G., Lewin S.R. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med. 2022; 14(629). doi: 10.1126/scitranslmed.abl3836.

21. Shah N.J., Al-Shbool G., Blackburn M., Cook M., Belouali A., Liu S.V., Madhavan S., He A.R., Atkins M.B., Gibney G.T., Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019; 7(1): 353. doi: 10.1186/s40425-019-0771-1.

22. Guihot A., Marcelin A.G., Massiani M.A., Samri A., Soulié C., Autran B., Spano J.P. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018; 29(2): 517–8. doi: 10.1093/annonc/mdx696.

23. Abbar B., Baron M., Katlama C., Marcelin A.G., Veyri M., Autran B., Guihot A., Spano J.P. Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects? AIDS. 2020; 34(2): 167–75. doi: 10.1097/QAD.0000000000002397.

24. Le Garff G., Samri A., Lambert-Niclot S., Even S., Lavolé A., Cadranel J., Spano J.P., Autran B., Marcelin A.G., Guihot A. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS. 2017; 31(7): 1048–51. doi: 10.1097/QAD.0000000000001429.

25. Klein N.C., Go C.H., Cunha B.A. Infections associated with steroid use. Infect Dis Clin North Am. 2001; 15(2): 423–32. doi: 10.1016/s0891-5520(05)70154-9.

26. Del Castillo M., Romero F.A., Argüello E., Kyi C., Postow M.A., Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clin Infect Dis. 2016; 63(11): 1490–3. doi: 10.1093/cid/ciw539.

27. Fujita K., Kim Y.H., Kanai O., Yoshida H., Mio T., Hirai T. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med. 2019; 146: 66–70. doi: 10.1016/j.rmed.2018.11.021.

28. Management of Immunotherapy-Related Toxicities [Internet]. NCCN Clinical Practice Guidelines in Oncology, Version 1.2022. URL: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. [cited 2022 Apr].

29. Prevention and Treatment of Cancer-Related Infections [Internet]. NCCN Clinical Practice Guidelines in Oncology, Version 1.2022. URL: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. [cited 2022 Apr].

30. Проценко С.А., Антимоник Н.Ю., Берштейн Л.М., Жукова Н.В., Новик А.В., Носов Д.А., Петенко Н.Н., Семенова А.И., Чубенко В.А., Харкевич Г.Ю., Юдин Д.И. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации RUSSCO. 2020; 10(#3s2). doi: 10.18027/22245057-2020-10-3s2-50.

31. Uchida N., Fujita K., Nakatani K., Mio T. Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab. Respirol Case Rep. 2017; 6(2). doi: 10.1002/rcr2.289.

32. Fujita K., Terashima T., Mio T. Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. J Thorac Oncol. 2016; 11(12): 2238–40. doi: 10.1016/j.jtho.2016.07.006.

33. Chu Y.C., Fang K.C., Chen H.C., Yeh Y.C., Tseng C.E., Chou T.Y., Lai C.L. Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma. J Thorac Oncol. 2017; 12(8): 111–4. doi: 10.1016/j.jtho.2017.03.012.

34. Zaemes J., Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020; 132: 168–75. doi: 10.1016/j.ejca.2020.03.015.

35. Langan E.A., Graetz V., Allerheiligen J., Zillikens D., Rupp J., Terheyden P. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020; 21(1): 55–65. doi: 10.1016/S1470-2045(19)30674-6.

36. Stroh G.R., Peikert T., Escalante P. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a nonendemic tuberculosis area. Cancer Immunol Immunother. 2021; 70(11): 3105–11. doi: 10.1007/s00262-021-02905-8.

37. Chang C.C., Sheikh V., Sereti I., French M.A. Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep. 2014; 11(3): 223–32. doi: 10.1007/s11904-014-0213-0.

38. Клинические рекомендации Министерства здравоохранения Российской Федерации «ВИЧ-инфекция у взрослых» [Internet]. 2020. URL: https://cr.minzdrav.gov.ru/schema/79_1. [cited 2022 Apr].

39. Oseso L.N., Chiao E.Y., Bender Ignacio R.A. Evaluating Antiretroviral Therapy Initiation in HIV-Associated Malignancy: Is There Enough Evidence to Inform Clinical Guidelines? J Natl Compr Canc Netw. 2018; 16(8): 927–32. doi: 10.6004/jnccn.2018.7057.

40. Боева Е.В., Беляков Н.А. Синдром восстановления иммунитета при ВИЧ-инфекции. Инфекция и иммунитет. 2018; 8(2): 139–49. doi: 10.15789/2220-7619-2018-2-139-149.

41. Riechelmann R.P., Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009; 20(12): 1907–12. doi: 10.1093/annonc/mdp369.

42. Gazzé G. Combination therapy for metastatic melanoma: a pharmacist’s role, drug interactions & complementary alternative therapies. Melanoma Manag. 2018; 5(2). doi: 10.2217/mmt-2017-0026.

43. Cortellini A., Tucci M., Adamo V., Stucci L.S., Russo A., Tanda E.T., Spagnolo F., Rastelli F., Bisonni R., Santini D., Russano M., Anesi C., Giusti R., Filetti M., Marchetti P., Botticelli A., Gelibter A., Occhipinti M.A., Marconcini R., Vitale M.G., Nicolardi L., Chiari R., Bareggi C., Nigro O., Tuzi A., De Tursi M., Petragnani N., Pala L., Bracarda S., Macrini S., Inno A., Zoratto F., Veltri E., Di Cocco B., Mallardo D., Vitale M.G., Pinato D.J., Porzio G., Ficorella C., Ascierto P.A. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020; 8(2). doi: 10.1136/jitc-2020-001361.

44. van Leeuwen R.W.F., Jansman F.G.A., van den Bemt P.M.L.A., de Man F., Piran F., Vincenten I., Jager A., Rijneveld A.W., Brugma J.D., Mathijssen R.H.J., van Gelder T. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015; 26(5): 992–7. doi: 10.1093/annonc/mdv029.

45. Olin J.L., Klibanov O., Chan A., Spooner L.M. Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. Ann Pharmacother. 2019; 53(8): 812–32. doi: 10.1177/1060028019833038.

46. Spano J.P., Poizot-Martin I., Costagliola D., Boué F., Rosmorduc O., Lavolé A., Choquet S., Heudel P.E., Leblond V., Gabarre J., Valantin M.A., Solas C., Guihot A., Carcelain G., Autran B., Katlama C., Quéro L. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol. 2016; 27(3): 397–408. doi: 10.1093/annonc/mdv606.

47. Drug interactions checker [Internet]. URL: https://www.drugs.com/drug_interactions.html. [cited 2022 Apr].

48. HIV drug interactions. [Internet]. URL: https://www.hiv-druginteractions.org/checker. [cited 2022 Apr].

49. Bressan S., Pierantoni A., Sharifi S., Facchini S., Quagliarello V., Berretta M., Montopoli M. Chemotherapy-Induced Hepatotoxicity in HIV Patients. Cells. 2021; 10(11): 2871. doi: 10.3390/cells10112871.

50. Centanni M., Moes D.J.A.R., Trocóniz I.F., Ciccolini J., van Hasselt J.G.C. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019; 58(7): 835–57. doi: 10.1007/s40262-019-00748-2.

51. Hussain N., Naeem M., Pinato D.J. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Hum Vaccin Immunother. 2021; 17(1): 55–61. doi: 10.1080/21645515.2020.1769398.

52. Sahin I.H., Kane S.R., Brutcher E., Guadagno J., Smith K.E., Wu C., Lesinski G.B., Gunthel C.J., El-Rayes B.F. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO Oncol Pract. 2020; 16(6): 319–25. doi: 10.1200/JOP.19.00754.

53. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. Geneva: World Health Organization; 2016.

54. Cancer in People Living With HIV [Internet]. NCCN Clinical Practice Guidelines in Oncology, Version 1.2022. URL: https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf. [cited 2022 Apr].

55. Gonzalez-Cao M., Puertolas T., Riveiro M., Muñoz-Couselo E., Ortiz C., Paredes R., Podzamczer D., Manzano J.L., Molto J., Revollo B., Carrera C., Mateu L., Fancelli S., Espinosa E., Clotet B., MartinezPicado J., Cerezuela P., Soria A., Marquez I., Mandala M., Berrocal A.; Spanish Melanoma Group (GEM). Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer. 2021; 9(3). doi: 10.1136/jitc-2020-001664. Erratum in: J Immunother Cancer. 2022; 10(2).

56. Elkington P.T., Bateman A.C., Thomas G.J., Ottensmeier C.H. Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. Am J Respir Crit Care Med. 2018; 198(11): 1451–3. doi: 10.1164/rccm.201807-1250LE.

57. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.

58. Ghrenassia E., Martis N., Boyer J., Burel-Vandenbos F., Mekinian A., Coppo P. The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun. 2015; 59: 19–25. doi: 10.1016/j.jaut.2015.01.010.

59. Пономарева Е.Ю., Шульдяков А.А., Анащенко А.В., Ребров А.П. Клиническая манифестация ВИЧ-инфекции, имитирующая ревматические заболевания. Научно-практическая ревматология. 2018; 56(4): 525–30.